DK1368060T3 - HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme - Google Patents
HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdommeInfo
- Publication number
- DK1368060T3 DK1368060T3 DK02717057.0T DK02717057T DK1368060T3 DK 1368060 T3 DK1368060 T3 DK 1368060T3 DK 02717057 T DK02717057 T DK 02717057T DK 1368060 T3 DK1368060 T3 DK 1368060T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- antagonists
- vascular disease
- protein inhibitors
- hmgb1 protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI000562A ITMI20010562A1 (it) | 2001-03-16 | 2001-03-16 | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
PCT/IT2002/000153 WO2002074337A1 (en) | 2001-03-16 | 2002-03-12 | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1368060T3 true DK1368060T3 (da) | 2010-08-30 |
Family
ID=11447291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02717057.0T DK1368060T3 (da) | 2001-03-16 | 2002-03-12 | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme |
Country Status (15)
Country | Link |
---|---|
US (4) | US7754217B2 (da) |
EP (1) | EP1368060B1 (da) |
JP (1) | JP4822654B2 (da) |
CN (2) | CN1537014B (da) |
AT (1) | ATE468137T1 (da) |
AU (1) | AU2002247977C1 (da) |
CA (1) | CA2439530C (da) |
DE (1) | DE60236413D1 (da) |
DK (1) | DK1368060T3 (da) |
ES (1) | ES2346408T3 (da) |
HK (1) | HK1069316A1 (da) |
IT (1) | ITMI20010562A1 (da) |
MX (1) | MXPA03008364A (da) |
PT (1) | PT1368060E (da) |
WO (1) | WO2002074337A1 (da) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
CA2447576C (en) * | 2001-05-15 | 2014-04-08 | North Shore-Long Island Jewish Research Institute | Use of hmg fragments as anti-inflammatory agents |
RU2005102593A (ru) | 2002-07-03 | 2005-10-10 | Фондационе Чентро Сан Раффаэле Дель Монте Табор (It) | Применение hmgb1 при лечении повреждения ткани и/или для промотирования восстановления ткани |
WO2004061456A2 (de) * | 2003-01-03 | 2004-07-22 | Alcedo Biotech Gmbh | Verwendungen von hmgb, hmgn, hmga proteinen |
US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
EP1668035A2 (en) | 2003-09-11 | 2006-06-14 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
ITRM20040058A1 (it) * | 2004-02-03 | 2004-05-03 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali. |
AU2005259381A1 (en) * | 2004-07-02 | 2006-01-12 | Creabilis Therapeutics S.P.A. | Nucleic acids for the treatment of HMGB1-related pathologies |
US20090062187A1 (en) | 2004-07-20 | 2009-03-05 | Marco Bianchi | Use of Hmgb1 for Wound Healing |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
WO2006024547A2 (en) * | 2004-09-03 | 2006-03-09 | Creabilis Therapeutics S.P.A. | Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
AU2005333602B2 (en) | 2004-10-22 | 2012-04-12 | Medimmune, Llc | High affinity antibodies against HMGB1 and methods of use thereof |
ITRM20050032A1 (it) * | 2005-01-21 | 2006-07-22 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica. |
WO2006114805A2 (en) * | 2005-04-28 | 2006-11-02 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb2 and hmgb3 proteins for medical applications |
US20100040608A1 (en) | 2005-07-18 | 2010-02-18 | Marie Wahren-Herlenius | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions |
EP1919979B2 (en) | 2005-08-25 | 2017-03-29 | Creabilis Therapeutics S.P.A. | Polymer conjugates of k-252a and derivatives thereof |
WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
CA2631212A1 (en) | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of hmgb1 and/or rage and methods of use thereof |
US7829097B2 (en) * | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
US8546547B2 (en) | 2006-09-15 | 2013-10-01 | Creabilis Therapeutics S.P.A. | Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1 |
US8470325B2 (en) | 2007-02-15 | 2013-06-25 | Kagoshima University | Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
CA2722909A1 (en) | 2008-04-30 | 2009-11-05 | Genomix Co., Ltd. | Method for collecting functional cells in vivo with high efficiency |
WO2009133939A1 (ja) | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 末梢循環への骨髄由来多能性幹細胞動員薬 |
EP2455469A4 (en) * | 2009-07-16 | 2013-03-13 | Nec Software Ltd | NUCLEIC ACID MOLECULE CAPABLE OF BINDING TO HMGB1 AND USE THEREOF |
JP5467313B2 (ja) | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
AU2010312537A1 (en) | 2009-10-28 | 2012-05-17 | Genomix Co., Ltd. | Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood |
JP6004494B2 (ja) * | 2010-10-30 | 2016-10-12 | オックスフォード ユニバーシティ イノベーション リミテッド | デュピュイトラン病の治療 |
PT3358011T (pt) | 2011-04-26 | 2020-04-23 | Univ Osaka | Péptido para induzir a regeneração de um tecido e a sua utilização |
WO2012170740A2 (en) * | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
RU2649069C2 (ru) | 2012-10-25 | 2018-04-02 | Дженомикс Ко., Лтд. | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 |
AU2013335684B2 (en) | 2012-10-25 | 2017-06-29 | Osaka University | Novel method for treating cardiac infarction using HMGB1 fragment |
SI2949675T1 (sl) | 2013-01-28 | 2021-08-31 | Evec Inc. | Humanizirano protitelo ANTI-HMGB1 ali njegov antigen-vezavni fragment |
IL242807A0 (en) | 2015-11-26 | 2016-04-21 | Novamed Ltd | Test facility |
US11274132B2 (en) | 2015-12-11 | 2022-03-15 | Ruprecht-Karls-Universität Heidelberg | Combined preparations of PKM2 modulators and HMGB1 |
US11298403B2 (en) | 2017-12-01 | 2022-04-12 | StemRIM Inc. | Therapeutic agent for inflammatory bowel disease |
AU2020449867A1 (en) * | 2020-04-22 | 2022-11-03 | Chulalongkorn University | A composition and a method of rejuvenating DNA and preventing DNA damage |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5470307A (en) * | 1994-03-16 | 1995-11-28 | Lindall; Arnold W. | Catheter system for controllably releasing a therapeutic agent at a remote tissue site |
WO1997026913A1 (en) | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
WO1997039121A1 (en) | 1996-04-16 | 1997-10-23 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US6398808B1 (en) * | 1999-06-15 | 2002-06-04 | Scimed Life Systems, Inc. | Localized delivery of genetic information from biostable materials |
US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
CA2447576C (en) * | 2001-05-15 | 2014-04-08 | North Shore-Long Island Jewish Research Institute | Use of hmg fragments as anti-inflammatory agents |
ITRM20040058A1 (it) * | 2004-02-03 | 2004-05-03 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali. |
US20090062187A1 (en) * | 2004-07-20 | 2009-03-05 | Marco Bianchi | Use of Hmgb1 for Wound Healing |
WO2008137552A2 (en) * | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anti-rage antibodies and methods of use thereof |
-
2001
- 2001-03-16 US US10/471,641 patent/US7754217B2/en not_active Expired - Fee Related
- 2001-03-16 IT IT2001MI000562A patent/ITMI20010562A1/it unknown
-
2002
- 2002-03-12 CA CA2439530A patent/CA2439530C/en not_active Expired - Fee Related
- 2002-03-12 CN CN028065670A patent/CN1537014B/zh not_active Expired - Fee Related
- 2002-03-12 PT PT02717057T patent/PT1368060E/pt unknown
- 2002-03-12 MX MXPA03008364A patent/MXPA03008364A/es active IP Right Grant
- 2002-03-12 WO PCT/IT2002/000153 patent/WO2002074337A1/en active Application Filing
- 2002-03-12 AU AU2002247977A patent/AU2002247977C1/en not_active Ceased
- 2002-03-12 EP EP02717057A patent/EP1368060B1/en not_active Expired - Lifetime
- 2002-03-12 DK DK02717057.0T patent/DK1368060T3/da active
- 2002-03-12 DE DE60236413T patent/DE60236413D1/de not_active Expired - Lifetime
- 2002-03-12 CN CN200910252323A patent/CN101773669A/zh active Pending
- 2002-03-12 AT AT02717057T patent/ATE468137T1/de active
- 2002-03-12 JP JP2002573044A patent/JP4822654B2/ja not_active Expired - Fee Related
- 2002-03-12 ES ES02717057T patent/ES2346408T3/es not_active Expired - Lifetime
-
2005
- 2005-03-02 HK HK05101837.0A patent/HK1069316A1/xx not_active IP Right Cessation
-
2008
- 2008-01-02 US US11/968,506 patent/US8058239B2/en not_active Expired - Fee Related
-
2010
- 2010-02-17 US US12/707,222 patent/US20100172896A1/en not_active Abandoned
- 2010-02-17 US US12/707,264 patent/US20100297107A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2439530C (en) | 2016-11-08 |
JP4822654B2 (ja) | 2011-11-24 |
ATE468137T1 (de) | 2010-06-15 |
US20100172896A1 (en) | 2010-07-08 |
US20080171052A1 (en) | 2008-07-17 |
CN101773669A (zh) | 2010-07-14 |
US20100297107A1 (en) | 2010-11-25 |
AU2002247977C1 (en) | 2008-09-18 |
ES2346408T3 (es) | 2010-10-15 |
CA2439530A1 (en) | 2002-09-26 |
DE60236413D1 (de) | 2010-07-01 |
EP1368060A1 (en) | 2003-12-10 |
AU2002247977A2 (en) | 2004-02-26 |
PT1368060E (pt) | 2010-08-24 |
WO2002074337A8 (en) | 2003-08-28 |
HK1069316A1 (en) | 2005-05-20 |
CN1537014B (zh) | 2012-04-25 |
US8058239B2 (en) | 2011-11-15 |
JP2004523579A (ja) | 2004-08-05 |
ITMI20010562A1 (it) | 2002-09-16 |
US20040136979A1 (en) | 2004-07-15 |
WO2002074337A1 (en) | 2002-09-26 |
CN1537014A (zh) | 2004-10-13 |
MXPA03008364A (es) | 2004-11-12 |
EP1368060B1 (en) | 2010-05-19 |
AU2002247977A1 (en) | 2002-10-03 |
US7754217B2 (en) | 2010-07-13 |
AU2002247977B8 (en) | 2007-03-15 |
AU2002247977B2 (en) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
ATE417037T1 (de) | Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen | |
DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
ATE315938T1 (de) | 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen | |
EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
BG66080B1 (bg) | Заместени тиоацетамиди | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
DK1411064T3 (da) | Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
SE0302304D0 (sv) | Novel compounds | |
DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
EA200400399A1 (ru) | Способы лечения легочных заболеваний | |
DE60206289D1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
DE60223707D1 (de) | Calcium-l-threonat zur behandlung von knochenfrakturen | |
EA200200853A1 (ru) | Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака | |
DE50212649D1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
DE60311822D1 (de) | Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen | |
NO20005548D0 (no) | Mykobakterieinhibitorer | |
DE69829995D1 (de) | Multivalente rekombinante antikörper zur behandlung von hrv infektionen | |
EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях |